Drugs / RGV004
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04887025 | Feb 2022 → Mar 2023 | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGV004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04887025 ↗ |